Exogenous glucagon-like peptide-1 attenuates glucose absorption and reduces blood glucose concentration after small intestinal glucose delivery in critical illness.

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

To evaluate the effect of exogenous glucagonlike peptide-1 (GLP-1) on small intestinal glucose absorption and blood glucose concentrations during critical illness.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

A prospective, blinded, placebo-controlled, cross-over, randomised trial in a mixed medical-surgical adult intensive care unit, with 12 mechanically ventilated critically ill patients, who were suitable for receiving small intestinal nutrient.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Glucagon study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

In the crossover set-up each of the participants took both Glucagon and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Critical Illness, Glucagon-Like Peptide 1, Glucose, Intestinal Absorption and Intestine, Small.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Glucagon.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine), a journal based in Netherlands.

More context: the Glucagon compound page, all human trials.